CINV

Question 1

LIST risk factors for CINV.

Question 2

Define acute CINV.

Answer 2

Within 24 hours (peak 4-6 hours)

Question 3

Define delayed CINV.

Answer 3

After 1-5 days (peak 2-3 days)

Question 4

Define anticipatory CINV.

Answer 4

Before therapy (sights, smells, sounds); risk factors (treatment > 6 months, h/o anxiety/depression, h/o poor anti-emetic control)

Question 5

Describe the QOL impact of CINV.

Question 6

Describe the pathophysiology of CINV.

Question 7

Describe the role of 5-HT and NK-1 in acute CINV.

Question 8

Describe the role of 5-HT and NK-1 in delayed CINV.

Question 9

Describe the MOA of 5-HT3 antagonists.

Question 10

Describe the MOA of corticosteroids.

Question 11

Describe the MOA of NK-1 antagonists.

Question 12

Describe the MOA of olanzapine.

Question 13

Describe the MOA of benzodiazepines.

Question 14

Describe the MOA of phenothiazines.

Question 15

Describe the MOA of butyrophenones.

Question 16

Describe the MOA of cannabinoids.

Question 17

LIST common side effects & potential drug related problems with 5-HT3 antagonists.

Question 18

LIST common side effects & potential drug related problems with corticosteroids.

Question 19

LIST common side effects & potential drug related problems with NK-1 antagonists.

Question 20

LIST common side effects & potential drug related problems with olanzapine.

Question 21

LIST common side effects & potential drug related problems with benzodiazepines.

Question 22

LIST common side effects & potential drug related problems with phenothiazines.

Question 23

LIST common side effects & potential drug related problems with butyrophenones.

Question 24

LIST common side effects & potential drug related problems with cannabinoids.

Question 25

Identify the common doses and brand/generic name of ondansetron.

Question 26

Identify the common doses and brand/generic name of palonosetron.

Question 27

Identify the common doses and brand/generic name of aprepitant/fosaprepitant.

Question 28

Identify the common doses and brand/generic name of prochlorperazine.

Question 29

Identify the common doses and brand/generic name of promethazine.

Question 30

Identify the common doses and brand/generic name of dexamethasone.

Question 31

Identify the common doses and brand/generic name of olanzapine.

Question 32

Summarize the evidence for agents used in treating and preventing CINV.

Question 33

Describe the principles of preventing CINV.

Question 34

Describe the principles of treating breakthrough CINV.

Question 35

LIST the goals of CINV treatment.

Question 36

Design a basic plan to prevent CINV.

Question 37

Summarize ASCO antiemetic guidelines by emetic risk category.

Question 38

Describe the rationale for different dexamethasone dosing with different NK-1 antagonists.

Question 39

Evaluate CINV clinical trial results.

Question 40

Use ASCO antiemetic guidelines to design regimens to prevent CINV.